The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments
Subscribe To Our Newsletter & Stay Updated
